[{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Norgine","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Undisclosed","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Takeda Pharmaceutical \/ Norgine","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Norgine"},{"orgOrder":0,"company":"University of Aarhus","sponsor":"Qufora","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"University of Aarhus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Aarhus \/ Qufora","highestDevelopmentStatusID":"1","companyTruncated":"University of Aarhus \/ Qufora"},{"orgOrder":0,"company":"Maastricht University Medical Center","sponsor":"Norgine","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"NETHERLANDS","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase IV","graph3":"Maastricht University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Maastricht University Medical Center \/ Norgine","highestDevelopmentStatusID":"11","companyTruncated":"Maastricht University Medical Center \/ Norgine"},{"orgOrder":0,"company":"University of Nottingham","sponsor":"Norgine","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"University of Nottingham","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"University of Nottingham \/ Norgine","highestDevelopmentStatusID":"11","companyTruncated":"University of Nottingham \/ Norgine"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Oncology","graph2":"Phase IV","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Norgine \/ Undisclosed"},{"orgOrder":0,"company":"Innovative Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"LEBANON","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Ophthalmology","graph2":"Phase IV","graph3":"Innovative Medical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Innovative Medical \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Innovative Medical \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"WellSpan Health","sponsor":"Neuraptive Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Neurology","graph2":"Phase I","graph3":"WellSpan Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WellSpan Health \/ Neuraptive Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"WellSpan Health \/ Neuraptive Therapeutics"},{"orgOrder":0,"company":"HyGIeaCare, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"HyGIeaCare, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HyGIeaCare, Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"HyGIeaCare, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Cleveland Clinic","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Cleveland Clinic","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cleveland Clinic \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Cleveland Clinic \/ Ferring Pharmaceuticals"},{"orgOrder":0,"company":"Alfredo Di Leo","sponsor":"Alfasigma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Nephrology","graph2":"Phase IV","graph3":"Alfredo Di Leo","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alfredo Di Leo \/ Alfasigma","highestDevelopmentStatusID":"11","companyTruncated":"Alfredo Di Leo \/ Alfasigma"},{"orgOrder":0,"company":"Devirex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Devirex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Devirex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Devirex \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis||PPA-gamma receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Norgine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Macrogol","moa":"Homeostasis||PPA-gamma receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Norgine \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Norgine \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Macrogol","moa":"PPA-gamma receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"EA Pharma","sponsor":"Mochida Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Macrogol","moa":"PPA-gamma receptor","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"EA Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder","sponsorNew":"EA Pharma \/ Mochida Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"EA Pharma \/ Mochida Pharmaceutical"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Macrogol","moa":"PPA-gamma receptor","graph1":"Gastroenterology","graph2":"Phase IV","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Macrogol","moa":"||PPA-gamma receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"NovaBay Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NovaBay Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Macrogol","moa":"||PPA-gamma receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"NovaBay Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NovaBay Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Macrogol","moa":"PPA-gamma receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Johnson & Johnson","amount2":0.11,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0.11,"dosageForm":"Solution","sponsorNew":"Johnson & Johnson \/ Bausch & Lomb Incorporated","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson \/ Bausch & Lomb Incorporated"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Macrogol","moa":"||PPA-gamma receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"NovaBay Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"NovaBay Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ColonaryConcepts","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Macrogol","moa":"||PPA-gamma receptor","graph1":"Gastroenterology","graph2":"Phase II","graph3":"ColonaryConcepts","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ColonaryConcepts \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ColonaryConcepts \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Macrogol 20000 (JP16)
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
